全文获取类型
收费全文 | 248篇 |
免费 | 16篇 |
国内免费 | 13篇 |
专业分类
儿科学 | 12篇 |
妇产科学 | 3篇 |
基础医学 | 9篇 |
口腔科学 | 2篇 |
临床医学 | 14篇 |
内科学 | 177篇 |
神经病学 | 1篇 |
特种医学 | 10篇 |
外科学 | 15篇 |
综合类 | 6篇 |
预防医学 | 5篇 |
眼科学 | 2篇 |
药学 | 18篇 |
肿瘤学 | 3篇 |
出版年
2024年 | 2篇 |
2023年 | 6篇 |
2022年 | 2篇 |
2021年 | 7篇 |
2020年 | 7篇 |
2019年 | 8篇 |
2018年 | 2篇 |
2017年 | 3篇 |
2016年 | 2篇 |
2015年 | 12篇 |
2014年 | 9篇 |
2013年 | 13篇 |
2012年 | 7篇 |
2011年 | 11篇 |
2010年 | 9篇 |
2009年 | 13篇 |
2008年 | 20篇 |
2007年 | 16篇 |
2006年 | 17篇 |
2005年 | 10篇 |
2004年 | 9篇 |
2003年 | 10篇 |
2002年 | 6篇 |
2001年 | 7篇 |
2000年 | 2篇 |
1999年 | 12篇 |
1998年 | 6篇 |
1997年 | 3篇 |
1996年 | 11篇 |
1995年 | 2篇 |
1994年 | 3篇 |
1993年 | 1篇 |
1992年 | 1篇 |
1991年 | 1篇 |
1990年 | 2篇 |
1989年 | 2篇 |
1988年 | 3篇 |
1987年 | 4篇 |
1986年 | 3篇 |
1985年 | 4篇 |
1982年 | 5篇 |
1980年 | 1篇 |
1978年 | 2篇 |
1976年 | 1篇 |
排序方式: 共有277条查询结果,搜索用时 6 毫秒
1.
2.
3.
Margarita Papatheodoridi Jean Baptiste Hiriart Monica Lupsor-Platon Fabrizio Bronte Jerome Boursier Omar Elshaarawy Fabio Marra Maja Thiele Georgios Markakis Audrey Payance Edgar Brodkin Laurent Castera George Papatheodoridis Aleksander Krag Umberto Arena Sebastian Mueller Paul Cales Vincenza Calvaruso Emmanuel A. Tsochatzis 《Journal of hepatology》2021,74(5):1109-1116
4.
Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease 总被引:26,自引:0,他引:26
Papatheodoridis GV Dimou E Laras A Papadimitropoulos V Hadziyannis SJ 《Hepatology (Baltimore, Md.)》2002,36(1):219-226
We studied the course of virologic breakthroughs detected by a quantitative polymerase chain reaction (PCR) assay in 32 of 78 patients with hepatitis B e antigen (HBeAg)-negative precore mutant hepatitis B virus (HBV) chronic liver disease under long-term lamivudine monotherapy. Serum HBV DNA levels were measured every 3 months and on every biochemical breakthrough. YMDD mutants were detected in 30 of the 32 patients with virologic breakthroughs. Among these 32 patients, biochemical remission rate was 44% at 6 months, 21% at 12 months, and 0% at 24 months after the onset of virologic breakthrough. Development of biochemical breakthroughs was associated with a significant increase of serum HBV DNA levels, which exceeded 100,000 copies/mL in 19 of 20 patients (95%) with biochemical breakthroughs and in only 1 of 8 patients (12.5%) remaining in biochemical remission for at least 6 months after the onset of virologic breakthrough (P <.001). Alanine aminotransferase (ALT) level peaked within 0 to 3 months after the onset of biochemical breakthrough and decreased at 6 months but remained abnormal in all but 2 patients. Follow-up liver histologic lesions in patients with biochemical breakthroughs did not differ from baseline findings, although they were significantly improved in patients remaining in virologic and biochemical remission. In conclusion, the frequent emergence of viral resistance under long-term lamivudine monotherapy in HBeAg-negative precore mutant HBV chronic liver disease is followed by increasing viremia levels culminating in the development of biochemical breakthroughs in most cases. ALT activity peaks close to the onset of biochemical breakthrough, decreasing thereafter but remaining persistently abnormal with fluctuating levels. 相似文献
5.
Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments 总被引:2,自引:0,他引:2
Sypsa V Touloumi G Papatheodoridis GV Tassopoulos NC Ketikoglou I Vafiadis I Hatzis G Tsantoulas D Akriviadis E Koutsounas S Hatzakis A 《Journal of viral hepatitis》2005,12(5):543-550
Summary. The epidemic of hepatitis C virus (HCV) infection is a major public health issue. We conducted a comprehensive analysis to estimate future HCV-related morbidity and mortality, using a model which is the first to take into account currently available treatments. We reconstructed the incident infections per year in the past that progressed to chronic hepatitis C (CHC) in Greece. Then, the natural history of the disease was simulated in subcohorts of newly infected subjects in the presence or absence of treatment using yearly estimates of the number of treated patients obtained from national databases. Annual estimates of the incidence and prevalence of CHC by fibrosis stage, hepatocellular carcinoma (HCC) and mortality were obtained up to 2030. The current proportion of naïve CHC patients receiving treatment in Greece is 1.2% per year. Treatment of 1.2–10% of naïve CHC patients per year would reduce the cumulative number of incident cirrhosis and HCC cases from 2002 to 2030 by 10.8–39.4% and 12.8–39.8%, respectively and decrease the number of prevalent cirrhosis and HCC cases in 2030 by approximately 17–48% compared with the number estimated under the assumption of no treatment. Approximately 17 cirrhosis cases or six HCC cases or 10 premature deaths would be prevented for every 100 treated patients. However, the prevalent cirrhotic/HCC cases because of HCV and HCV-related deaths would not plateau until 2030. Despite the introduction of effective treatment, HCV-related morbidity and mortality will likely increase during the next 20–30 years in Greece. Intensive primary prevention efforts coupled with increased access to the currently available treatments are necessary to control the chronic consequences of HCV epidemic. 相似文献
6.
Fotinie Ntziora Dimitrios Paraskevis Catherine Haida Emanuel Manesis George Papatheodoridis Spilios Manolakopoulos Ioannis Elefsiniotis Timokratis Karamitros Alexis Vassilakis Angelos Hatzakis 《Journal of clinical microbiology》2013,51(9):2893-2900
Resistance to antiviral treatment for chronic hepatitis B virus (HBV) has been associated with mutations in the HBV polymerase region. This study aimed at developing an ultrasensitive method for quantifying viral populations with all major HBV resistance-associated mutations, combining the amplification refractory mutation system real-time PCR (ARMS RT-PCR) with a molecular beacon using a LightCycler. The discriminatory ability of this method, the ARMS RT-PCR with molecular beacon assay, was 0.01 to 0.25% for the different HBV resistance-associated mutations, as determined by laboratory-synthesized wild-type (WT) and mutant (Mut) target sequences. The assay showed 100% sensitivity for the detection of mutant variants A181V, T184A, and N236T in samples from 41 chronically HBV-infected patients under antiviral therapy who had developed resistance-associated mutations detected by direct PCR Sanger sequencing. The ratio of mutant to wild-type viral populations (the Mut/WT ratio) was >1% in 38 (63.3%) of 60 samples from chronically HBV-infected nucleos(t)ide analogue-naive patients; combinations of mutations were also detected in half of these samples. The ARMS RT-PCR with molecular beacon assay achieved high sensitivity and discriminatory ability compared to the gold standard of direct PCR Sanger sequencing in identifying resistant viral populations in chronically HBV-infected patients receiving antiviral therapy. Apart from the dominant clones, other quasispecies were also quantified. In samples from chronically HBV-infected nucleos(t)ide analogue-naive patients, the assay proved to be a useful tool in detecting minor variant populations before the initiation of the treatment. These observations need further evaluation with prospective studies before they can be implemented in daily practice. 相似文献
7.
8.
Margarita Papatheodoridi Emilia Hadziyannis Franoise Berby Kalliopi Zachou Barbara Testoni Eirini Rigopoulou Nikolaos K. Gatselis Aggeliki Lyberopoulou Ioannis Vlachogiannakos Spilios Manolakopoulos George N. Dalekos Fabien Zoulim George V. Papatheodoridis 《Journal of viral hepatitis》2020,27(2):118-126
Reliable predictors of outcomes after treatment discontinuation in HBeAg‐negative chronic hepatitis B (CHB) patients have not been established. We investigated the role of hepatitis B surface antigen (HBsAg), interferon‐inducible protein‐10 (IP10) and hepatitis B core‐related antigen (HBcrAg) serum levels as predictors of HBsAg loss, relapse and retreatment in noncirrhotic HBeAg‐negative CHB patients who discontinued long‐term antiviral therapy. All HBsAg‐positive (n = 57) patients of the prospective DARING‐B study were included and followed monthly for 3 months, every 2/3 months until month‐12 and every 3/6 months thereafter. HBsAg, IP10 and HBcrAg levels were measured by enzyme immunoassays, and SCALE‐B score was calculated. Twelve patients achieved HBsAg loss before retreatment with 18‐month cumulative incidence of 25%. Independent predictors of HBsAg loss were baseline HBsAg and month‐1 IP10 levels. Of 10 patients with baseline HBsAg ≤100 IU/mL, 70% cleared HBsAg and 10% required retreatment. Of 23 patients with baseline HBsAg >1000 IU/mL, 4% cleared HBsAg and 43% required retreatment. Of 24 patients with intermediate baseline HBsAg (100‐1000 IU/mL), 17% cleared HBsAg and 21% required retreatment; in this subgroup, month‐1 IP10 was significantly associated with HBsAg loss, which occurred in 30% and 7% of cases with IP10 >150 and ≤150 pg/mL, respectively. Baseline HBcrAg was undetectable in all patients who cleared HBsAg and was associated with retreatment. SCALE‐B was associated with HBsAg loss but not with relapse or retreatment. In conclusion, HBsAg, IP10 and HBcrAg serum levels can be useful for the decisions and management of treatment discontinuation in noncirrhotic Caucasian patients with HBeAg‐negative CHB. 相似文献
9.
10.
Angelos Hatzakis Jeffrey V. Lazarus Evangelos Cholongitas Ricardo Baptista‐Leite Charles Boucher Cristian‐Silviu Busoi Sylvie Deuffic‐Burban Jagpreet Chhatwal Gamal Esmat Sharon Hutchinson Minerva‐Melpomeni Malliori Mojca Maticic Antons Mozalevskis Francesco Negro George A. Papandreou George V. Papatheodoridis Markus Peck‐Radosavljevic Homie Razavi Tatjana Reic Eberhard Schatz Nurdan Tozun Zobair Younossi Michael P. Manns 《Liver international》2020,40(2):260-270
The majority of people infected with chronic hepatitis C virus (HCV) in the European Union (EU) remain undiagnosed and untreated. During recent years, immigration to EU has further increased HCV prevalence. It has been estimated that, out of the 4.2 million adults affected by HCV infection in the 31 EU/ European Economic Area (EEA) countries, as many as 580 000 are migrants. Additionally, HCV is highly prevalent and under addressed in Eastern Europe. In 2013, the introduction of highly effective treatments for HCV with direct‐acting antivirals created an unprecedented opportunity to cure almost all patients, reduce HCV transmission and eliminate the disease. However, in many settings, HCV elimination poses a serious challenge for countries’ health spending. On 6 June 2018, the Hepatitis B and C Public Policy Association held the 2nd EU HCV Policy summit. It was emphasized that key stakeholders should work collaboratively since only a few countries in the EU are on track to achieve HCV elimination by 2030. In particular, more effort is needed for universal screening. The micro‐elimination approach in specific populations is less complex and less costly than country‐wide elimination programmes and is an important first step in many settings. Preliminary data suggest that implementation of the World Health Organization (WHO) Global Health Sector Strategy on Viral Hepatitis can be cost saving. However, innovative financing mechanisms are needed to raise funds upfront for scaling up screening, treatment and harm reduction interventions that can lead to HCV elimination by 2030, the stated goal of the WHO. 相似文献